Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring

Journal of Immunotherapy

Volumn 27, Issue 2, 2004, Pages 161-175

  McDonald, Donald M ^a   Teicher, Beverly A ^b   Stetler Stevenson, William ^c   Ng, Sylvia S W ^d   Figg, William D ^c   Folkman, Judah ^d   Hanahan, Douglas ^a   Auerbach, Robert ^e   O'Reilly, Michael ^f   Herbst, Roy ^f   Cheresh, David ^g   Gordon, Michael ^h   Eggermont, Alexander ⁱ   Libutti, Steven K ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENZYME CORPORATION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Models; Therapy; Tumor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ABT 726; ANGIOGENESIS INHIBITOR; BATIMASTAT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; ERLOTINIB; FLUOROURACIL; IMATINIB; INTEGRIN ANTIBODY; MELPHALAN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PROTEIN ANTIBODY; SEMAXANIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ASSAY; BIOLOGICAL MONITORING; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DOSE RESPONSE; DRUG INDUSTRY; DRUG SCREENING; GOVERNMENT; HUMAN; MEDICAL SOCIETY; MOLECULAR BIOLOGY; NONHUMAN; ORGANIZATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; TUMOR VASCULARIZATION; WORKSHOP;

EID: 10744230105     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200403000-00010     Document Type: Conference Paper

References (69)

1. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
2. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404-2407.
3. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol. 2001;13:563-568.
4. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815-1822.
5. Bello L, Zhang J, Nikas DC, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas. Neurosurgery. 2000;47:1185-1195.
6. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500-1502.
7. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J. 2000;6(Suppl 3):S245-S249.
8. Eliceiri BP, Klemke R, Stromblad S, et al. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998;140:1255-1263.
9. Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 1999;4:915-924.
10. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002;2:826-835.
11. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 2001;7:1194-1201.
12. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 2003;17:604-611.
13. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156:1363-1380.
14. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607-4612.
15. Morikawa S, Baluk P, Kaidoh T, et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160:985-1000.
16. Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543-554.
17. Hellstrom M. Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126:3047-3055.
18. Abramsson A, Berlin O, Papayan H, et al. Analysis of mural cell recruitment to tumor vessels. Circulation. 2002;105:112-117.
19. Hanahan D, Christofori G, Naik P, et al. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer. 1996;32A:2386-2393.
20. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nature Med. 2003;9(b):713-725.
21. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol. 1995;9:1760-1770.
22. Grunstem J, Roberts WG, Mathieu-Costello O, et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 1999;59:1592-1598.
23. Inoue M, Hager JH, Ferrara N, et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 2002;1:193-202.
24. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2000;2:737-744.
25. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol. 2003;220:545-554.
26. Kerbel RS, Klement G, Pritchard KI, et al. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002;13:12-15.
27. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
28. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731-2735.
29. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
30. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
31. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
33. Folkman J, Browder T. and Palmblad, J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemostas. 2001;86:23-33.
34. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
35. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus 1FL (ironotecan, 5-flurourasil, leucovorin) as first line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol. 39 Meeting, Chicago, IL.
36. Jain RK, Schlenger K, Hockel M, et al. Quantitative angiogenesis assays: progress and problems. Nature Med. 1997;3:203-208.
37. Auerbach R, Akhtar N, Lewis RL, et al. Angiogenesis assays: problems and pitfalls. Cancer Metast Rev. 2000;19:167-172.
38. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
39. Akeson AL, Brooks SK, Thompson FY, et al. In vitro model for developmental progression from vasculogenesis to angiogenesis with a murine endothelial presursor cell line, MFLM-4. Microvasc Res. 2001;61:75-86.
40. Burbridge MF, West DC. Rat aorta ring. In: Murray JC, ed. Methods in Molecular Medicine: Angiogenesis Protocols, Vol 46. Totowa, NJ: Humana Press, 2001;185-204.
41. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest. 1990;63:115-122.
42. Kruger EA, Duray PH, Tsokos MG, et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun. 2000;268:183-191.
43. Hendrix MJC, Seftor EA, Hess AR, et al. Molecular plasticity of human melanoma cells. Oncogene. 2003;22:3070-3075.
44. Guedez L, Rivera A, Salloum R, et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol. 2003;162:1431-1439.
45. Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am. 2002;16:1125-1171.
46. Kim ES, Herbst RS. Angiogenesis inhibitors in lung cancer. Curr Oncol Rep. 2002;4:325-333.
47. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
48. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002;20:3792-3803.
49. Herbst RS, Madden TL, Tran HT, et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol. 2002;20:4440-4447.
50. Davis DW, McConkey DJ, Abbruzzese JL, et al. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8-14.
51. 99mTc-EC-endostatin. Cancer Biother Radiopharm. 2002;17:233-245.
52. Eder JP Jr, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002;20:3772-3784.
53. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-739.
54. Mininberg ED, Herbst RS, Henderson T, et al. Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). Proc ASCO, 39th Meeting, Chicago, IL, 2003.
55. Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol. 2001;13:261-269.
56. Heymach J, Kulke MH, Fuchs CS, et al. Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin. Proc ASCO, 39th Meeting, Chicago, IL, 2003.
57. Stam TC, Swaak AJ, de Vries MR, et al. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol. 2000;7:268-275.
58. van Etten B, van Geel AN, de Wilt JH, et al. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol. 2003;10:32-37.
59. de Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 1999;80:161-166.
60. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer. 2000;82:1000-1003.
61. de Wilt JH, Manusama ER, van Etten B, et al. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer. 2000;83:1176-1182.
62. Seynhaeve AL, de Wilt JH, van Tiel ST, et al. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer. 2002;86:1174-1179.
63. van Etten B, de Vries MR, van Ijken, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer. 2003;88:314-319.
64. Ten Hagen TL, Van Der Veen AH, Nooijen PT, et al. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer. 2000;87:829-837.
65. ten Hagen TL, Seynhaeve AL, van Tiel ST, et al. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer. 2002;97:115-120.
66. Eggermont AMM, De Wilt JHW, Ten Hagen TLM. Current uses of isolated limb perfusion in the clinica and a model system for new strategies. Lancet Oncol. 2003;4:429-437.
67. Margolin K, Gordon MS, Holmgren E, et al. Phase 1b trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851-856.
68. Gordon MS. Vascular endothelial growth factor as a target for antiangiogenic therapy. J Clin Oncol. 2000;18:45S-46S.
69. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-850.